March 11, 2022 01:48 PM ESTUpdated 02:42 PM
Pharma
Manufacturing

More in­spec­tion trou­ble for Zy­dus just a day af­ter big ac­qui­si­tion

Josh Sullivan

An FDA in­spec­tion at In­dia’s Zy­dus Life­sciences’ fa­cil­i­ty has re­sult­ed in three ob­ser­va­tions, the com­pa­ny re­vealed Thurs­day.

The an­nounce­ment comes af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

A service from the Financial Times